Chinanews.com, Shanghai, May 13 (Reporter Chen Jing) The reporter learned on the 13th that the results of a study conducted by a well-known Chinese expert as the world’s main researcher showed that compared with sorafenib, Carrelizad ( Erica®) monoclonal antibody combined with apatinib (Aitan®) (also known as “Double Ai” regimen) as first-line therapy can significantly prolong progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
95 centers from 13 countries and regions around the world participated in this randomized controlled, open-label, international multi-center phase III clinical study (SHR-1210-III-310 study), Nanjing Jinling Hospital Cancer Center Professor Qin Shukui of the Center serves as the global principal investigator. Camrelizumab is a humanized PD-1 monoclonal antibody independently developed by Chinese pharmaceutical company Hengrui Medicine with intellectual property rights. 8 indications have been approved in the five major tumor types of cancer and lymphoma; apatinib is also a small molecule tyrosine kinase inhibitor developed by Hengrui Medicine. Currently, 2 indications have been approved, one for advanced gastric adenocarcinoma Or gastroesophageal junction adenocarcinoma, advanced hepatocellular carcinoma.
In primary liver cancer (abbreviation: liver cancer), hepatocellular carcinoma accounts for 90%. It is understood that the treatment of hepatocellular carcinoma chooses different therapies according to the stage of the disease. The treatment of advanced hepatocellular carcinoma is mainly based on systemic anti-tumor therapy. Although the new combination therapy has improved the survival of patients with advanced hepatocellular carcinoma to a certain extent, but There is still much room for improvement, and more effective treatment options are urgently needed.
In recent years, Hengrui Medicine has promoted the clinical research of “Shuangai” combination in multiple tumor types. Previously, the “Double Ai” program entered the national standard for diagnosis and treatment of liver cancer, providing a new option for standardized treatment of liver cancer. At the 2022 Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines Conference held not long ago, the “Double Ai” program received several recommendations. According to reports, based on the SHR-1210-III-310 study, the indication of camrelizumab for the treatment of advanced hepatocellular carcinoma has also obtained the US FDA orphan drug qualification, and it is expected to enjoy policy support in the follow-up research and development and commercialization. (End)